Live price temporarily unavailable.
Karyopharm Therapeutics (KPTI) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $154.0K | $1.60M | $30.3M | $40.9M | $108.1M | $209.8M | $157.1M | $146.0M | $145.2M | $146.1M |
| Growth (year over year) | −38.4% | +942.2% | +1790.1% | +34.8% | +164.3% | +94.1% | −25.1% | −7.0% | −0.5% | +0.6% |
| Operating income | −$110.7M | −$130.5M | −$179.9M | −$189.3M | −$171.8M | −$98.3M | −$142.2M | −$129.5M | −$119.4M | −$90.7M |
| Operating margin | −71903.9% | −8133.2% | −593.0% | −462.9% | −159.0% | −46.8% | −90.5% | −88.7% | −82.2% | −62.1% |
| Net income | −$109.6M | −$129.0M | −$178.4M | −$199.6M | −$196.3M | −$124.1M | −$165.3M | −$143.1M | −$76.4M | −$196.0M |
| Net margin | −71153.9% | −8036.4% | −588.1% | −488.1% | −181.6% | −59.1% | −105.2% | −98.0% | −52.6% | −134.2% |
| EPS (diluted) | −$657.00 | −$632.25 | −$706.50 | −$724.50 | −$40.80 | −$24.75 | −$30.30 | −$18.79 | −$14.00 | −$17.93 |
| Balance sheet | ||||||||||
| Cash and equivalents | $49.7M | $69.0M | $118.0M | $128.9M | $85.9M | $190.5M | $135.2M | $52.2M | $62.5M | $60.5M |
| Total assets | $180.4M | $180.3M | $341.2M | $295.0M | $313.1M | $305.3M | $358.2M | $240.4M | $164.4M | $108.4M |
| Total liabilities | $18.1M | $50.8M | $158.0M | $245.2M | $262.5M | $385.0M | $374.8M | $376.6M | $350.4M | $401.3M |
| Long-term debt | — | — | — | — | — | $169.3M | — | — | — | — |
| Shareholders' equity | $162.2M | $129.5M | $183.2M | $49.8M | $50.5M | −$79.7M | −$16.7M | −$136.2M | −$186.0M | −$292.9M |
| Cash flow | ||||||||||
| Operating cash flow | −$84.4M | −$73.7M | −$159.1M | −$190.8M | −$160.2M | −$107.1M | −$149.6M | −$92.7M | −$127.5M | −$75.4M |
| Capital expenditure | $70.0K | $62.0K | $2.36M | $206.0K | $145.0K | $212.0K | $118.0K | $0 | $142.0K | $0 |
| Free cash flow | −$84.5M | −$73.8M | −$161.5M | −$191.0M | −$160.4M | −$107.3M | −$149.7M | −$92.7M | −$127.6M | −$75.4M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $38.8M | $30.5M | $30.0M | $37.9M | $44.0M | $34.1M | $35.1M | $33.4M |
| Growth (year over year) | +7.7% | −9.5% | −9.4% | −11.4% | +13.6% | +11.6% | +16.8% | −11.9% |
| Operating income | −$26.3M | −$31.3M | −$33.3M | −$24.4M | −$15.2M | −$17.8M | −$26.8M | −$22.5M |
| Operating margin | −67.8% | −102.4% | −110.8% | −64.3% | −34.6% | −52.4% | −76.3% | −67.4% |
| Net income | −$32.1M | −$30.8M | −$23.5M | −$37.3M | −$33.1M | −$102.2M | −$22.4M | −$67.0M |
| Net margin | −82.7% | −100.8% | −78.2% | −98.2% | −75.2% | −299.9% | −63.9% | −200.5% |
| EPS (diluted) | −$3.85 | −$2.33 | −$2.77 | −$4.32 | −$3.82 | −$7.02 | −$1.24 | −$2.32 |
| Balance sheet | ||||||||
| Cash and equivalents | $72.8M | $62.5M | $38.8M | $38.7M | $37.7M | $60.5M | $90.8M | $55.0M |
| Total assets | $189.5M | $164.4M | $127.7M | $104.9M | $96.2M | $108.4M | $131.4M | $111.3M |
| Total liabilities | $349.1M | $350.4M | $333.6M | $343.8M | $365.5M | $401.3M | $397.1M | $441.5M |
| Shareholders' equity | −$159.6M | −$186.0M | −$205.9M | −$238.9M | −$269.3M | −$292.9M | −$265.6M | −$330.2M |
| Cash flow | ||||||||
| Operating cash flow | −$19.5M | −$25.8M | −$39.0M | −$18.7M | −$5.86M | −$11.8M | −$22.7M | −$24.9M |
| Capital expenditure | $0 | −$53.0K | $0 | $0 | $0 | $0 | — | — |
| Free cash flow | −$19.5M | −$25.8M | −$39.0M | −$18.7M | −$5.86M | −$11.8M | — | — |
From Karyopharm Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Karyopharm Therapeutics in our feed yet.